Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
about
Novel therapeutic strategies targeting HIV integraseIncomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsClinical use of HIV integrase inhibitors: a systematic review and meta-analysisThe VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) studyInitiation of antiretroviral therapy.Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or CEfficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirThe potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsExtended use of raltegravir in the treatment of HIV-1 infection: optimizing therapyEffect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.Role of raltegravir in the management of HIV-1 infection.Long-term safety from the raltegravir clinical development program.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapyCost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsA switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort studyPharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgePotential benefit of dolutegravir once daily: efficacy and safety.Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patientsIncidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitnessP-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceEffect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.The use of integrase inhibitors in treatment-experienced patients.
P2860
Q27003960-D7CE5FCC-7F2B-412D-88E6-EF185696BEE6Q27021524-7577A973-B98A-44D9-B6F2-32E12B8BBF66Q28481393-22D8EB30-3EFF-405D-B7BE-4EAC9985CDAAQ28484930-28430B1C-9F0C-408A-A2C9-E81E0D189F52Q28541478-66FD297D-1E82-4213-BB64-467C676F4BCAQ30209635-9CAF444D-805D-48BC-BF02-71750F1ACCA3Q33940800-067F009B-9D52-4631-A59C-6E9DEAFE9876Q33945171-CB430AF8-C0C5-4D90-8CBF-115A1A9308A8Q34059119-29F5245F-FE28-4953-9F7F-8A869A9939FDQ34341541-096E9CAF-C0E0-4DD4-AA47-4D7E8A0E0172Q34529127-08CF0534-303F-4CC8-B3B9-7807D57A8CB7Q34606231-30A85508-BAED-49F5-B519-C6CCD9DDAE2EQ34730950-BAB18F71-16D6-4277-8C44-6CFDBBE4F772Q35026582-B394754E-B4A6-4DDA-B3B3-876A1DDCDDC8Q35120618-F9D971A8-C1B4-4DDF-B47A-0BBD091F6FB4Q35385630-50983378-8BDD-4866-A37B-D768977D4036Q35557318-F3E43503-5D8D-41AA-8A46-B5DC2184BA32Q35701258-C9010663-9A1E-4ACF-9E03-731BBF7113C0Q35770848-7DD9311F-BCCD-43C6-AB5D-1F0FBD225F52Q35867491-7FD63EE4-136C-4B63-9769-ED00AF73DB3EQ35880715-B5E29C58-D108-4733-94A4-AEE0FD223623Q35896106-E5C21360-829F-4C31-AE94-CCD0A723C159Q35944477-76507418-F5D1-4835-8CE8-F3E906CB2E98Q36018635-42D539A7-0DB4-4CC5-8DF1-E5AE91C02A06Q36250418-F73C015E-FF8A-4B60-AE13-F41727757EB8Q36284159-C2452E89-28CF-4D76-8310-B805B2C2FFFCQ36311771-41515D46-E3F2-47A4-9816-C96676391AADQ36337077-B0B89042-6E0E-4571-BE67-BA2852EA81E9Q36377397-74EBC72B-41AD-47ED-B4BD-AC9621BE1962Q36603416-380B8BE7-F249-41A0-803A-80D84EDA3D7DQ36715890-E9A89FCB-E031-4CD1-8728-D7D00BD6DE1AQ36759898-8311ADA5-3DF2-488F-B535-3598A5A4A716Q37026630-69240302-72B6-4A05-A781-54CC2021BC6BQ37273923-F1BDBA3D-250F-43C1-A766-314A0C329744Q37288671-BC9E0D4F-D93D-4A95-A2F9-FC73869EF656Q37462061-FB8BF24A-5346-40F2-8564-C5D20399BCC9Q37473017-B7301303-4BAC-4D09-A045-123EE8F48F7EQ37473023-C2324721-7BEC-4A2B-A1E2-4E7626126849Q37598398-8BB52E23-F957-40A4-981C-EE32762716CBQ37644122-C766CEF9-DC35-4D26-9CE5-904A91475EA2
P2860
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@en
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@nl
type
label
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@en
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@nl
prefLabel
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@en
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@nl
P2093
P2860
P50
P356
P1476
Long-term efficacy and safety ...... HMRK 1 and 2 Phase III trials.
@en
P2093
BENCHMRK Study Teamsa
Bach-Yen T Nguyen
David A Cooper
Hedy Teppler
Jeffrey L Lennox
Jose M Gatell
Kim M Strohmaier
Martin Markowitz
P2860
P304
P356
10.1086/650002
P407
P577
2010-02-01T00:00:00Z